FluoroPharma Medical, Inc. FPMI

FPMI Company Overview

FluoroPharma Medical, Inc. (FPMI) is a molecular imaging and radiopharmaceutical development company focused on diagnostic agents used in positron emission tomography (PET) imaging. The company has historically operated within the healthcare, biotechnology, and nuclear medicine industries, with an emphasis on cardiovascular and oncology imaging technologies. Its primary business objective has been the development of fluorine-18–based PET imaging compounds intended to improve the detection and characterization of disease processes such as coronary artery disease and cancer.

The company’s principal value proposition centered on developing PET tracers with longer half-lives and potentially broader clinical utility compared with traditional imaging isotopes. Public filings and historical investor materials indicate that FPMI pursued proprietary radiopharmaceutical candidates designed to support non-invasive imaging and diagnostic workflows. The company evolved from an early-stage diagnostic imaging developer into a clinically focused radiopharmaceutical enterprise; however, publicly available information regarding recent commercialization progress, revenue scale, or active operating status remains limited. Data inconclusive based on available public sources regarding the company’s current commercial operations.